Novel parenteral carbamazepine formulation

Abstract

The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.

1 . A carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine comprising a carbamazepine complexed with a modified cyclodextrin. 
     
     
         2 . The complex of  claim 1  wherein said modified cyclodextrin is a sulfoalkyl-cyclodextrin. 
     
     
         3 . The complex of  claim 1  or  2  wherein said modified cyclodextrin is sulfobutylether-7-beta-cyclodextrin. 
     
     
         4 . The complex of  claim 1  having a concentration of about 5 to about 50 mg/ml carbamazepine. 
     
     
         5 . The complex of  claim 1  having a concentration of about 10 mg/ml carbamazepine. 
     
     
         6 . A carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine in which dosing is about 30% to about 100% of oral maintenance doses. 
     
     
         7 . The complex of  claim 6  wherein said dosing is about 65% to 75% of oral maintenance doses. 
     
     
         8 . A carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine having a half-life of about 8 to about 65 hours. 
     
     
         9 . The complex of  claim 8  having a half-life of about 24 hours. 
     
     
         10 . A carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine having an area under the plasma concentration-time curve (AUC) of about 70% to about 130% of the AUC for an oral carbamazepine dosage form. 
     
     
         11 . The complex of  claim 10  having an AUC of about 80% to about 125% of the AUC for an oral carbamazepine dosage form. 
     
     
         12 . A carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine having a minimum plasma concentration (Cmin) of about. 70% to about 130% of the Cmin for an oral carbamazepine dosage form. 
     
     
         13 . The complex of  claim 12  having a Cmin of about 80% to about 125% of the Cmin for an oral carbamazepine dosage form. 
     
     
         14 . A carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine having an intravenous dosing interval of every four to twelve hours. 
     
     
         15 . The complex of  claim 14  having an intravenous dosing interval of every six hours. 
     
     
         16 . The complex of  claim 14  having an intravenous dosing interval of every eight hours. 
     
     
         17 . A method of administering a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine comprising: 1) providing a carbamazepine-cyclodextrin inclusion complex; and 2) infusing said complex intravenously to a patient in need thereof every four to twelve hours. 
     
     
         18 . The method of  claim 17  wherein the period of said infusing occurs over about 5 to about 60 minutes. 
     
     
         19 . The method of  claim 17  wherein the period of said infusing occurs over 30 minutes. 
     
     
         20 . The method of  claim 17  wherein the period of said infusing occurs over 5 minutes. 
     
     
         21 . The method of  claim 17  wherein said infusing is done every six hours. 
     
     
         22 . The method of  claim 17  wherein said infusing is done every eight hours. 
     
     
         23 . A method of preparing a carbamazepine-cyclodextrin inclusion complex by admixing a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid to form a carbamazepine-cyclodextrin inclusion complex. 
     
     
         24 . The method of  claim 23  further including the step of sterilizing said carbamazepine-cyclodextrin inclusion complex. 
     
     
         25 . The method of  claim 23  wherein said physiologically acceptable fluid is isotonic. 
     
     
         26 . The method of  claim 23  wherein said modified cyclodextrin is a sulfoalkyl-cyclodextrin. 
     
     
         27 . The method of  claim 23  wherein said modified cyclodextrin is sulfobutylether-7-betacyclodextrin.